|
1
|
He L and Hannon GJ: MicroRNAs: small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
4
|
Fabbri M, Croce CM and Calin GA:
MicroRNAs. Cancer J. 14:1–6. 2008. View Article : Google Scholar
|
|
5
|
Slaby O, Bienertova-Vasku J, Svoboda M and
Vyzula R: Genetic polymorphisms and microRNAs: new direction in
molecular epidemiology of solid cancer. J Cell Mol Med. 16:8–21.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Curtin NJ, Harris AL and Aherne GW:
Mechanism of cell death following thymidylate synthase inhibition:
2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and
growth inhibition following exposure to CB3717 and dipyridamole.
Cancer Res. 51:2346–2352. 1991.
|
|
8
|
Peters GJ, van Triest B, Backus HH, Kuiper
CM, van der Wilt CL and Pinedo HM: Molecular downstream events and
induction of thymidylate synthase in mutant and wild-type p53 colon
cancer cell lines after treatment with 5-fluorouracil and the
thymidylate synthase inhibitor raltitrexed. Eur J Cancer.
36:916–924. 2000. View Article : Google Scholar
|
|
9
|
Giacchettii S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000.
|
|
10
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar
|
|
11
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
12
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
13
|
Kim JW and Dang CV: Cancer’s molecular
sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930.
2006.
|
|
14
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
7:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Doherty JR and Cleveland JL: Targeting
lactate metabolism for cancer therapeutics. J Clin Invest.
123:3685–3692. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Y, Tozzi F, Chen J, Fan F, Xia L,
Wang J, et al: Intracellular ATP levels are a pivotal determinant
of chemoresistance in colon cancer cells. Cancer Res. 72:304–314.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akao Y, Nakagawa I, Hirata I, Iio A, Itoh
T, Kojima K, Nakashima R, Kitade Y and Naoe T: Role of
anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer
Gene Ther. 17:398–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rokhlin OW, Scheinker VS, Taghiyev AF,
Bumcrot D, Glover RA and Cohen MB: MicroRNA-34 mediates
AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol
Ther. 7:1288–1296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan D, Zhou X, Chen X, Hu DN, Dong XD,
Wang J, et al: MicroRNA-34a inhibits uveal melanoma cell
proliferation and migration through downregulation of c-Met. Invest
Ophthalmol Vis Sci. 50:1559–1565. 2009. View Article : Google Scholar
|
|
24
|
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R,
et al: Downregulation of CCND1 and CDK6 by miR-34a induces cell
cycle arrest. FEBS Lett. 582:1564–1568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei JS, Song YK, Durinck S, Chen QR, Cheuk
AT, Tsang P, et al: The MYCN oncogene is a direct target of
miR-34a. Oncogene. 27:5204–5213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang F, Li QJ, Gong ZB, Zhou L, You N,
Wang S, Li XL, Li JJ, An JZ, Wang DS, et al: MicroRNA-34a targets
Bcl-2 and sensitizes human hepatocellular carcinoma cells to
sorafenib treatment. Technol Cancer Res Treat. 13:77–86.
2014.PubMed/NCBI
|
|
28
|
Ji Q, Hao X, Meng Y, Zhang M, Desano J,
Fan D and Xu L: Restoration of tumor suppressor miR-34 inhibits
human p53-mutant gastric cancer tumorspheres. BMC Cancer.
8:2662008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koukourakis I, Giatromanolaki A and
Sivridis E: Colorectal cancer: Lactate dehydrogenase (LDH) activity
as a prognostic marker. Methods of Cancer Diagnosis, Therapy, and
Prognosis. Springer; Berlin, Germany: 4. pp. 241–253. 2009
|
